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Strengths and limitations of this study
 ► To our knowledge, this is the first systematic review 
that formally analyses and compares the diagnostic 
accuracy of currently available point- of- care tests 
for urinary tract infections (UTIs) diagnosis.
 ► The results from this study will help identify the best 
available point- of- care test to diagnose UTIs in the 
primary care setting.
 ► It is likely that significant heterogeneity will be found 
as all available tests will be explored, and meta- 
analysis will be performed to account for this.
 ► Studies involving paediatric population (<18 years 
old) or populations with certain conditions (detailed 
in exclusion criteria) will be excluded, as well as 
studies aimed at screening of asymptomatic bacte-
riuria, which may affect the generalisability of the 
results out with these situations.
AbStrACt
Introduction Urinary tract infections (UTIs) are the second 
most common type of infection worldwide, accounting 
for a large number of primary care consultations and 
antibiotic prescribing. Current diagnosis is based on an 
empirical approach, relying on symptoms and occasional 
use of urine dipsticks. The diagnostic reference standard is 
still urine culture, although it is not routinely recommended 
for uncomplicated UTIs in the community, due to time 
to diagnosis (48 hours). Faster point- of- care tests have 
been developed, but their diagnostic accuracy has not 
been compared. Our objective is to systematically review 
and meta- analyse the diagnostic accuracy of currently 
available point- of- care tests for UTIs.
Methods and analysis Studies evaluating the diagnostic 
accuracy of point- of- care tests for UTIs will be included. 
PubMed, Web of Science, Embase and Cochrane 
Database of Systematic Reviews were searched from 
inception to 1 June 2019. Data extraction and risk- of- bias 
assessment will be assessed using the Quality Assessment 
of Diagnostic Accuracy Studies tool. Meta- analysis 
will be performed depending on data availability and 
heterogeneity.
Ethics and dissemination This is a systematic review 
protocol and therefore formal ethical approval is not 
required, as no primary, identifiable, personal data will be 
collected. Patients or the public were not involved in the 
design of our research. However, the findings from this 
review will be shared with key stakeholders, including 
patient groups, clinicians and guideline developers, and 
will also be presented and national and international 
conferences.
PrOSPErO registration number CRD42018112019.
IntrOduCtIOn
Urinary tract infections (UTIs) are the 
second most common cause of infection 
in primary1 and secondary care2 and most 
women experience at least one episode of 
acute uncomplicated cystitis in their life-
time. In the UK, UTIs account for 1%–3% of 
all consultations in primary care each year.1 
UTIs are also responsible for a major part of 
antibiotic prescriptions, accounting for up to 
15% of antimicrobial use in the community, 
with antibiotic use been described as one of 
the main factors contributing to the emer-
gence of antimicrobial resistance (AMR).3 
The rise of AMR has been postulated as one 
of the major challenges for healthcare world-
wide.4 It is related to increased morbidity, 
mortality and cost, particularly in vulnerable 
populations such as the elderly.4 The WHO 
Global Action Plan to Reduce Antimicrobial 
Resistance5 includes improving antimicro-
bial use across all human and animal health, 
and environment settings through a One 
Health approach. Rates of AMR among gram- 
negative bacteria have progressively increased 
in the last decade in the European Union 
(EU),6 with particularly concerning rise of 
carbapenemase- producing and extended- 
spectrum- beta- lactamase organisms.7
Currently, most clinical guidelines recom-
mend that primary care diagnosis and 
management of uncomplicated UTI should 
be done empirically,8 9 thus based on clinical 
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Table 1 Inclusion criteria
Participants: Adults
Presentation: Symptomatic UTIs (variously 
defined)13
Index test(s): Any point- of- care diagnostic 
test
Target condition: Urinary tract infections
Reference standard: Urine culture
UTIs, urinary tract infections.
symptoms. Although this approach has proven to be 
cost effective,10 prescribing without diagnostic certainty 
increases the use of potentially unnecessary antibiotics, 
and contributes to the problem of AMR.11 Up to 90% of 
patients presenting to primary care with urinary symp-
toms receive an antibiotic7 12 but it is usually without 
further investigation, so it is unclear how many will 
have a proven infection. Available evidence on how well 
symptoms predict the presence of a true UTI has shown 
diverging results, when compared with gold standard 
(urine culture). The probability of a female patient 
presenting to primary care with typical UTI symptoms and 
having a confirmed infection is estimated to be between 
50%–80%, with the greatest predictability for haematuria, 
and if combined with a positive urine dipstick.13 14 There-
fore, alternative tests with enhanced diagnostic accuracy 
could potentially reduce inappropriate antimicrobial use 
in this context.
The gold standard for UTI diagnosis is urine culture 
from a midstream, clean urine catch, but as previously 
mentioned, urine culture is not always performed, 
especially in primary care and emergency departments, 
where diagnosis of most UTIs occurs.15 Urine culture is 
slow, requiring at least 24–48 hours to report the caus-
ative microorganism and provide an antibiotic resistance 
profile,16 and symptoms are usually distressing enough to 
prompt on the day empirical management, since acutely 
unwell patients with UTI symptoms may not be prepared 
to wait up to 48 hours for a culture result. Current clin-
ical guidelines also advocate empirical treatment if symp-
toms are sufficiently suggestive of a diagnosis of UTI.9 
Empirical decision- making will often result in the patient 
getting an antibiotic without infection confirmation. 
As result of this, different point- of- care tests (POCT) 
have been developed aiming to provide a more rapid 
and accurate method for detecting infection. POCT 
has been defined as ‘a test to support clinical decision 
making, performed nearby the patient and on any part 
of the patient’s body or its derivates, to help the patient 
and healthcare professional on the best management 
approach during or very close to the time of the consul-
tation, with results available at the time of clinical deci-
sion making’.17 POCT diagnostic accuracy is influenced 
dramatically from pretest probability in different subpop-
ulations18 and consequently, its ability to detect or discard 
infection can be variable.19 20 Potentially, an ‘ideal’ POCT 
would allow for more timely identification of UTIs, facil-
itating improved, targeted treatment, and reduced inap-
propriate antibiotic use. Indirect methods, such as urine 
dipsticks, which detect host inflammatory response rather 
than bacterial presence, have become the main POCT for 
UTIs.21 Other techniques include culture- based devices, 
enzymatic assays and semiautomated urine analysers.22 
Previous reports suggest that their diagnostic accuracy 
could be greater than that of simpler urine dipsticks.16 
These tests could provide relevant information to clini-
cians to prescribe antimicrobials more accurately, 
reducing antibiotic- related harms (including resistance), 
and costs.23 However, it is difficult to ascertain which 
POCT could be better for diagnosing UTIs, in general, 
and in specific situations.
Our aim is to systematically review and meta- analyse the 
diagnostic test accuracy of currently available POCTs for 
UTIs, as compared with gold standard (urine culture).
MEthOdS And AnAlySIS
Eligibility criteria
Randomised clinical trials (RCTs), cluster RCTs, evaluation 
studies, observational studies and regulatory or approval 
evidence reports (if available), evaluating point- of- care 
diagnostic tests for UTI in symptomatic patients versus 
urine culture (reference standard)7 will be included, 
from both primary or secondary care settings. No partic-
ular index test was prespecified in our review search 
criteria, as we aimed to capture and compare all available 
tests. However, only those tests that could be categorised 
as ‘point- of- care test’ will be included, defined as above.17 
Inclusion criteria are detailed in table 1, following the 
PIRD (Participants, Index test, Target condition, Refer-
ence standard) approach for including studies in system-
atic reviews of diagnostic test accuracy.24
The search strategy uses broad terms for defining UTI 
with the aim of capturing all potentially relevant studies 
looking at POCT used in symptomatic UTIs. Classical 
symptoms include those mentioned in table 1, and we will 
also examine different symptoms/combinations and UTI 
definition used in each study. Exclusion criteria will be 
applied and are detailed below. These include:
 ► Studies evaluating the detection of asymptomatic 
bacteriuria in pregnancy.
 ► Studies performed only in children.
 ► Tests aimed at detecting sexually transmitted infec-
tions, or non- bacterial infections (eg, schistosomiasis).
 ► Tests based on biomarkers needing laboratory 
facilities.
 ► Studies whose main outcome measure is to detect 
complications of urinary infections (eg, CT scans or 
other imaging techniques).
 ► Clinical algorithms or self- reported symptom tests.
 ► Specific populations will be excluded: urinary cath-
eterised patients, kidney transplantation, terminal 
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kidney failure or immunocompromised patients, 
patients with spinal cord injury or neurogenic bladder.
Information sources and search
Medline, Web of Science, Embase and Cochrane Data-
base of Systematic Reviews were searched from database 
inception to 1 June 2019 with no language restrictions. 
Only studies involving human health were included. 
The search included a combination of the following 
terms: “Urinary Tract Infections/diagnosis”, “Diagnostic 
Tests, Routine”, “Point- of- Care Systems”, “Point- of- Care 
Testing”, “point- of- care testing”, ‘near- patient testing’, 
‘RDT’, “poct”, “Diagnostic Technics and Procedures”, 
“Techni* and Procedures, Diagnostic”, “rapid diagnostic 
test*”, AND “Urinary Tract Infections”, “Pyuria”, “Bacte-
riuria”, “uti”, AND “sensitivity”, “specificity”, “likelihood 
ratio”, “predictive value”, “diagnostic accuracy”, “AUC”, 
“PPV”, “NPV”, among other. The full search strategy is 
available in online supplementary appendix 1 and online 
in PROSPERO’s database.25
data management
Search results will be stored in EndNote V.X8.2 bibliog-
raphy management software. To synthetise and develop 
study selection, data extraction and quality assessment, 
we will use Covidence platform.26
Study selection
Three reviewers (DFN, AAL and VHS) will independently 
assess study eligibility for inclusion. A calibration exer-
cise assessing 10% of the results by title and abstract will 
be done in duplicate. After title and abstract screening, 
selected articles will be screened full text. Discrepancies 
will be solved by discussion. Another reviewer will be 
involved as necessary (FS).
data collection process
A standardised data extraction form will be developed. 
The review team (DFN, AAL and VHS) will independently 
extract the data from all studies. Study authors will be 
contacted if no data are available. All articles will be 
double extracted, and risk of bias will be double assessed. 
Discrepancies will be evaluated and solved by discussion, 
and if no agreement, a third reviewer will be involved.
diagnostic accuracy measures
A 2×2 contingency table with true positives, true nega-
tives, false positives and false negatives will be extracted 
from each study. Accuracy outcome measures will include: 
sensitivity, specificity, positive and negative predictive 
values.
definitions for data extraction
From each study, besides the accuracy- related data already 
specified, we will extract the following predefined set of 
characteristics:
 ► Device/product name.
 ► Manufacturer/country of origin.
 ► Regulatory approval status in the EU and USA.
 ► Type of sample used (clean urine midstream catch, 
or other).
 ► Method principle (culture- based, enzymatic assay, 
other).
 ► Analysis time (time required, in minutes).
 ► Additional training required.
 ► Need for supplementary equipment (eg, steriliser, 
centrifuge, etc).
 ► Cost.
 ► Type of result provided if the test is positive (presence 
of infection, bacterial load, antibiotic sensitivity, indi-
rect method for detection).
 ► The threshold for positivity detection, in unit forming 
colonies.
 ► Population tested.
 ► UTI definition used.
 ► Secondary outcomes: mortality, hospitalisation, 
quality of life measures and/or patients’ preferences, 
if reported.
risk of bias
Methodological quality assessment will be conducted 
using the Quality Assessment of Diagnostic Accuracy 
Studies tool.27
Synthesis of results
A narrative description summarising the prespecified 
characteristics of each test, and a paired sensitivity–spec-
ificity forest plot, will be provided. Meta- analysis will 
be performed depending on available data, sources of 
heterogeneity, comparability between methods and ability 
to aggregate data. If enough data are available, random- 
effect meta- analysis will be performed for each index test. 
The bivariate model will be used to ascertain summary 
sensitivity and specificity if all studies in the group use 
the same threshold value for positivity. If index tests use 
different threshold values, the hierarchical summary 
receiver operating characteristic (HSROC)model will be 
used instead, to obtain summary sensitivity and specificity 
for each threshold value. Sources of heterogeneity will 
be investigated, regarding index test used, threshold for 
detection, target population included in the study and 
its given (if reported) pretest probability. Subgroup anal-
ysis will be explored and performed depending on the 
heterogeneity found and available data, analysing sepa-
rately studies looking at each POCT and also different 
population groups (differentiating adults from elderly 
patients).
Patients and public involvement
Patients or the public were not involved in the design 
of our research. However, the findings from this review 
will be shared with key stakeholders, including patient 
groups, clinicians and guideline developers, and will 
also be presented and national and international 
conferences.
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EthICS And dISSEMInAtIOn
Ethical approval was explored with the University of 
St Andrews School of Medicine Research and Ethics 
Committee but was not necessary due to the nature of the 
research (literature review). Results from this review will 
be shared with key stakeholders, including patient groups, 
clinicians and guideline developers, and will potentially 
inform future diagnostic and treatment pathways.
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